Fluconazole in the treatment of cutaneous leishmaniasis caused by leishmania braziliensis: A randomized controlled trial

Clinical Infectious Diseases

Volumn 64, Issue 1, 2017, Pages 67-71

  De Prates, Fernanda V O ^a   Dourado, Mayra E F ^a   Silva, Silvana C ^a   Schriefer, Albert ^a,b   Guimarães, Luiz H ^a,b   Brito, Maria Das Graças O ^a   Almeida, Juliana ^a   Carvalho, Edgar M ^a,b   Machado, Paulo R L ^a,b  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

Author keywords

Cutaneous leishmaniasis; Fluconazole; Leishmania (V.) braziliensis; Pentavalent antimony

Indexed keywords

FLUCONAZOLE; MEGLUMINE ANTIMONATE; ANTIMONY; ANTIPROTOZOAL AGENT;

ADULT; ANOREXIA; ANTIPROTOZOAL THERAPY; ARTHRALGIA; ARTICLE; BRAZIL; COMPARATIVE STUDY; CONTROLLED STUDY; DIZZINESS; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FEVER; HEADACHE; HUMAN; INTENTION TO TREAT ANALYSIS; LEISHMANIA BRAZILIENSIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MYALGIA; NAUSEA; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKIN LEISHMANIASIS; TREATMENT DURATION; VOMITING; WEAKNESS; ADOLESCENT; CLINICAL TRIAL; DRUG EFFECTS; GENETICS; MIDDLE AGED; PARASITOLOGY; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIMONY; ANTIPROTOZOAL AGENTS; BRAZIL; FEMALE; FLUCONAZOLE; HUMANS; LEISHMANIA BRAZILIENSIS; LEISHMANIASIS, CUTANEOUS; MALE; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85015168020     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciw662     Document Type: Article

References (38)

1. Ministério da Saúde, Secretaria de Vigilância em Saúde. Manual de vigilância da leishmaniose tegumentar americana. 2nd ed. Available at: http://bvsms.saude.gov.br/bvs/publicacoes/manual-vigilancia-leishmaniose-2ed.pdf. Accessed 3 May 2015.
2. Jirmanus L, Marshall JG, Guimarães LH, et al. Epidemiological and clinical changes in American tegumentary leishmaniasis in an area of Leishmania (Viannia) braziliensis transmission over a 20-year period. Am J Trop Med Hyg 2012; 86:426-33.
3. Arana B, Rizzo N, Diaz A. Chemotherapy of cutaneous leishmaniasis: A review. Med Microbiol Immunol 2001; 190:93-5.
4. Romero GA, Guerra MVF, Paes MG, et al. Comparison of cutaneous leishmaniasis due to Leishmania (Viannia) braziliensis and L. (V.) guyanensis in Brazil: Therapeutic response to meglumine antimoniate. Am J Trop Med Hyg 2001; 65:456-65.
5. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19:111-26.
6. Santos JB, Jesus AR, Machado PR, et al. Antimony plus recombinant human granulocyte- macrophage colony-stimulating factor applied topically in low doses enhances healing of cutaneous leishmaniasis ulcers: A randomized, double-blind, placebo-controlled study. J Infect Dis 2004; 190:1793-6.
7. Machado PRL, Rosa MEA, Schriefer A. American tegumentary leishmaniasis in Bahia, Brazil. Nederlands Tijdschrift voor Dermatologie En Venereologie 2010; 20:645-9.
8. Bailey MS, Lockwood DN. Cutaneous leishmaniasis. Clin Dermatol 2007; 25:203-11.
9. Reveiz L, Maia-Elkhoury ANS, Nicholls RS, Sierra GAR, Yadon ZE. Interventions for American cutaneous and mucocutaneous leishmaniasis: A systematic review update. PLoS One 2013; 8:618-43.
10. Machado PR, Ampuero J, Guimarães LH, et al. Miltefosine in the treatment of cutaneous leishmaniasis caused by Leishmania braziliensis in Brazil: A randomized and controlled trial. PLoS Negl Trop Dis 2010; 4:e912.
11. Beach DH, Goad LJ, Holz GG Jr. Effects of antimycotic azoles on growth and sterol biosynthesis of Leishmania promastigotes. Mol Biochem Parasitol 1988; 31:149-62.
12. Albanese G, Giorgetti P, Santagostino L, Crippa D, Sala G. Cutaneous leishmaniasis: Treatment with itraconazole. Arch Dermatol Res 1989; 125:1540-2.
13. Al-Abdely HM, Graybill JR, Loebenberg D, Melby PC. Efficacy of triazole SCH56592 against Leishmania amazonensis and Leishmania donovani in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 1999; 43:2910-4.
14. Alrajhi AA, Ibrahim EA, De Vol EB, Khairat M, Faris RM, Maguire JH. Fluconazole for the treatment of cutaneous leishmaniasis caused by Leishmania major. N Engl J Med 2002; 346:891-5.
15. Baron S, Laube S, Raafat F, Moss C. Cutaneous leishmaniasis in a Kosovan child treated with oral fluconazole. Clin Exp Dermatol 2004; 29:545-62.
16. Nassiri-Kashani M, Firooz A, Khamesipour A, et al. A randomized, double-blind, placebo-controlled clinical trial of itraconazole in the treatment of cutaneous leishmaniasis. J Eur Acad Dermatol Venereol 2005; 19:80-3.
17. Rafaa M, Ingen-Housz-Oro S, Méry L, et al. Traitement par fluconazole de la leishmaniose cutanée chez l'enfant. Ann Dermatol Venereol 2007; 134:682-7.
18. Sklavos AV, Walls T, Webber MT, Watson AB. Cutaneous leishmaniasis in a child treated with oral fluconazole. Australas J Dermatol 2010; 51:195-7.
19. Daly K, Lima HD, Kato H, et al. Intermediate cutaneous leishmaniasis caused by Leishmania (Viannia) braziliensis successfully treated with fluconazole. Clin Exp Dermatol 2014; 39:708-12.
20. Sousa AQ, Frutuoso MS, Moraes EA, Pearson RD, Pompeu MML. High-dose oral fluconazole therapy effective for cutaneous leishmaniasis due to Leishmania (Vianna) braziliensis. Clin Infect Dis 2011; 53:693-5.
21. Brammer KW, Farrow PR, Faulkner JK. Pharmacokinetics and tissue penetration of fluconazole in humans. Rev Infect Dis 1990; 12:318-26.
22. Wildfeuer A, Faergemann J, Laufen H, et al. Bioavailability of fluconazole in the skin after oral medication. Mycoses 1994; 37:127-30.
23. Weirather JL, Jeronimo SM, Gautam S, et al. Serial quantitative PCR assay for detection, species discrimination, and quantification of Leishmania spp. in human samples. J Clin Microbiol 2011; 49:3892-04.
24. Machado P, Araújo C, Silva AT, et al. Failure of early treatment of cutaneous leishmaniasis in preventing the development of an ulcer. Clin Infect Dis 2002; 34:69-73.
25. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13:176-81.
26. Hadighi R, Mohebali M, Boucher P, Hajjaran H, Khamesipour A, Quellette M. Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites. PLoS Med 2006; 3:e162.
27. Solomon M, Baum S, Barzilai A, Scope A, Trau H, Schwartz E. Liposomal amphotericin B in comparison to sodium stibogluconate for cutaneous infection due to Leishmania braziliensis. J Am Acad Dermatol 2007; 56:612-6.
28. Llanos-Cuentas A, Tulliano G, Araujo-Castillo R, et al. Clinical and parasite species risk factors for pentavalent antimonial treatment failure in cutaneous leishmaniasis in Peru. Clin Infect Dis 2008; 46:223-31.
29. Neves LO, Talhari AC, Gadelha EP, et al. A randomized clinical trial comparing meglumine antimoniate, pentamidine and amphotericin B for the treatment of cutaneous leishmaniasis by Leishmania guyanensis. An Bras Dermatol 2011; 86:1092-101.
30. Emad M, Hayati F, Fallahzadeh MK, Namazi MR. Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous Leishmania major infection: A randomized clinical trial. J Am Acad Dermatol 2011; 64:606-8.
31. Arevalo J, Ramirez L, Adaui V, et al. Influence of Leishmania (Viannia) species on the response to antimonial treatment in patients with American tegumentary leishmaniasis. J Infect Dis 2007; 195:1846-51.
32. World Health Organization. Control of leishmaniasis: report of the meeting of the WHO Expert Committee on the control of leishmaniases. Available at: http://apps.who.int/iris/bitstream/10665/44412/1/WHO-TRS-949-eng.pdf. Accessed 3 May 2015.
33. Barral-Neto M, Machado P, Barral A. Human cutaneous leishmaniasis: recent advances in physiopathology and treatment. Eur J Dermatol 1995; 5:104-13.
34. Queiroz A, Sousa R, Heine C, et al. Association between an emerging disseminated form of leishmaniasis and Leishmania (Viannia) braziliensis strain polymorphisms. J Clin Microbiol 2012; 50:4028-34.
35. Unger A, O'Neal S, Machado PR, et al. Association of treatment of American cutaneous leishmaniasis prior to ulcer development with high rate of failure in Northeastern Brazil. Am J Trop Med Hyg 2009; 80:574-9.
36. Machado PR, Lessa H, Lessa M, et al. Oral pentoxifylline combined with pentavalent antimony: A randomized trial for mucosal leishmaniasis. Clin Infect Dis 2007; 44:788-93.
37. Grimaldi G Jr, Porrozzi R, Friedrich K, et al. Comparative efficacies of two antimony regimens to treat Leishmania braziliensis-induced cutaneous leishmaniasis in rhesus macaques (Macaca mulatta). Antimicrob Agents Chemother 2010; 54:502-5.
38. Schubach A, Cuzzi-Maya T, Oliveira AV, et al. Leishmanial antigens in the diagnosis of active lesions and ancient scars of American tegumentary leishmaniasis patients. Mem Inst Oswaldo Cruz 2001; 96:987-96.